GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » 908 Devices Inc (NAS:MASS) » Definitions » Altman Z-Score

908 Devices (908 Devices) Altman Z-Score : 2.80 (As of May. 11, 2024)


View and export this data going back to 2020. Start your Free Trial

What is 908 Devices Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of 2.8 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

908 Devices has a Altman Z-Score of 2.80, indicating it is in Grey Zones. This implies that 908 Devices is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for 908 Devices's Altman Z-Score or its related term are showing as below:

MASS' s Altman Z-Score Range Over the Past 10 Years
Min: 2.74   Med: 7.21   Max: 23.82
Current: 2.8

During the past 6 years, 908 Devices's highest Altman Z-Score was 23.82. The lowest was 2.74. And the median was 7.21.


908 Devices Altman Z-Score Historical Data

The historical data trend for 908 Devices's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

908 Devices Altman Z-Score Chart

908 Devices Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial - 23.82 10.86 2.74 5.21

908 Devices Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.04 3.19 2.78 5.21 3.75

Competitive Comparison of 908 Devices's Altman Z-Score

For the Medical Devices subindustry, 908 Devices's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


908 Devices's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, 908 Devices's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where 908 Devices's Altman Z-Score falls into.



908 Devices Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

908 Devices's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.751+1.4*-0.9564+3.3*-0.1863+0.6*5.975+1.0*0.2673
=2.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2024:
Total Assets was $189.79 Mil.
Total Current Assets was $161.87 Mil.
Total Current Liabilities was $19.33 Mil.
Retained Earnings was $-181.52 Mil.
Pre-Tax Income was -10.987 + -7.431 + -7.18 + -9.417 = $-35.02 Mil.
Interest Expense was 0 + 0 + 0.35 + 0 = $0.35 Mil.
Revenue was 9.991 + 14.351 + 14.297 + 12.094 = $50.73 Mil.
Market Cap (Today) was $196.57 Mil.
Total Liabilities was $32.90 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(161.868 - 19.33)/189.791
=0.751

X2=Retained Earnings/Total Assets
=-181.516/189.791
=-0.9564

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-35.015 - 0.35)/189.791
=-0.1863

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=196.566/32.898
=5.975

X5=Revenue/Total Assets
=50.733/189.791
=0.2673

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

908 Devices has a Altman Z-Score of 2.80 indicating it is in Grey Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


908 Devices  (NAS:MASS) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


908 Devices Altman Z-Score Related Terms

Thank you for viewing the detailed overview of 908 Devices's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


908 Devices (908 Devices) Business Description

Traded in Other Exchanges
N/A
Address
645 Summer Street, Boston, MA, USA, 02210
908 Devices Inc manufactures medical devices. It has developed an innovative suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets.
Executives
Griffith Joseph H. Iv officer: Chief Financial Officer 68 ELM STREET, HOPKINTON MA 01748
Christopher D. Brown officer: Chief Technology Officer C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Kevin J. Knopp director, officer: President and CEO C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Michael S. Turner officer: VP, General Counsel C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Maura Fitzpatrick officer: VP, Product Management & Mktg 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Mark Spoto director C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Michele Fournier officer: Chief People Officer 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Trent A. Basarsky officer: Vice President, Commercial C/O PROTEINSIMPLE, 3040 OAKMEAD VILLAGE DRIVE, SANTA CLARA CA 95051
John Kenneweg officer: Vice President, Government C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Anthony Hunt director 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Nicolas Barthelemy director 1750 BELLA LAGUNA CT, ENCINITAS CA 92024
Marcia Eisenberg director C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Jeffrey P. George director C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Fenel M Eloi director C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452
Keith Crandell director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631